Multiple mechanisms of resistance contribute to the inevitable progression of hormone-
sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved …

Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to
castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for …

Prostate cancer is the second leading cause of cancer deaths in the USA. The challenge in
managing castration-resistant prostate cancer (CRPC) stems not from the lack of therapeutic …

Context After initiation of androgen deprivation therapy (ADT), most patients progress to
castration-resistant prostate cancer (CRPC) within 2 or 3 yr. In the USA, approximately 67 …

Simple Summary Castration-resistant prostate cancer (CRPC) remains a significant medical
challenge, even with recent advancements in diagnosis and treatment. To improve patient …

In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …

After initial response to androgen receptor (AR) targeting drugs abiraterone or
enzalutamide, most patients develop progressive disease and therefore, castration resistant …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients
progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling …